This interview with Robert Giugliano from Brigham and Women's Hospital, Boston, US discusses the Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab (FOURIER).

Filmed by Radcliffe Cardiology on-site at ESC 2017.